/Company Directory

/

BOTBotanix Pharmaceuticals

$57M3mo

Companies/BOT

BOTActiveTier 1

Botanix Pharmaceuticals

Biotech · Dermatology

Dermatology-focused with FDA-approved SOFDRA for hyperhidrosis

Website ↗ASX ↗

Cash data from Mar 2026 4CFigures from ASX filings · not financial advice

[ VITALS ]

Cash on Hand

$22.1M

Mar 2026 4C

Runway

3moCRITICAL

Based on Mar 2026 4C

Market Cap

$57M

Burn Rate

$23.3M/qtr

Mar 2026 4C

Shares Outstanding

2.7B

Pipeline Assets

BOT

Latest Insightprice-sensitive announcements & broker notes

Price-sensitiveQuarterly 4C28 Apr 2026

Botanix Quarterly Activities Report and Appendix 4C Q3 FY26

Cash$22.1M·Burn$23.3M/q·OCF$-23.3M

picture_as_pdfView full announcement

3M Price

BOT.ASX

$0.020-61.5% 3M

Low $0.020High $0.052

Pipeline Assets (2)

BX002Acne vulgaris

Phase 2

SOFDRA (sofpironium)Primary axillary hyperhidrosis

Approved

Discovery

Preclinical

Ph 1

Ph 1/2

Ph 2

Ph 2/3

Ph 3

NDA

Capital Raises & Buybacks

12mo dilution 31.7%12mo $5M2 raises

Current shares outstanding: 2.7B

SPP

2026-03-11sppUpdate to SPP prospectus issuing 777,777,778 unquoted options exercisable at $0.06 on or before 31 January 2027, offered to placement participants, SPP participants, and underwriters, subject to shareholder approval on 1 April 2026.

777.8M sh0

2026-03-11sppSPP underwritten to $5 million at $0.06 per share, open 11 March to 13 April 2026, with maximum individual subscription of $30,000 and subject to shareholder approval on 1 April 2026.

Other ticker data

Insider activity, holders, grants, publications

expand ›

Director Transactions

6 transactions

Last 90dNet Buy

Buys3+3 vs prior

Sells0

Buy Value$250k

warning3 directors bought within 30 days (04-10 – 04-10) — $250k total

OPTIONS EXERCISEVincent Peter Ippolito

Catalysts (23)· 1 upcoming · 22 past

BX002 Phase 2 acne topline data

Upcoming

Expectedarrow_upwardHigh30 June 2026

expand_more22 past catalysts

SOFDRA quarterly revenue update

Completed

Confirmedarrow_upwardHigh28 Apr 2026

Quarterly update filed (auto-resolved)

Results posted — A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosisopen_in_new

Completed

Track Record

Delivery Consistency Index

expand ›

Historical delivery and spending consistency. Data is limited for recently added companies.

Delivery Consistency Index

Delivery

–Insufficient data

2/3 data points needed

Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts

Capital discipline

Med61/100

Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus

Hit 2 of 2 guided dates· rolling 2yr(limited sample)· of 23 tracked

Filing discipline not scored — this company reports under US regime (Form 10-K / 10-Q). ASX Listing Rule 4.7C deadlines don't apply.

What drove these scores · rolling 2yr

arrow_drop_down

Volatile burn rate — 65% quarterly variation — inconsistent spend

arrow_drop_down

1 burn spike — Quarter-on-quarter spend increase >50%

arrow_drop_down

Cash position declining — Cash balance dropped >30% over last 3 quarters

arrow_drop_up

Burn reductions achieved — 1 quarter with >30% spend reduction

arrow_drop_up

R&D-focused spend — 82% of opex directed to R&D

Mixed cash flow — Burn volatility calculated from 5 burning quarters only

Phase 3+ thresholds — Burn rate variability thresholds adjusted for late-stage development

Completed catalysts

✓AAD 2026 presentation· presentation — scheduled date— Presented at AAD 2026 annual meeting (Mar 26-29, San Francisco)

On time

✓SOFDRA quarterly revenue update— Quarterly update filed (auto-resolved)

2d early

Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.

These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.

Announcements(20)

All announcements →

article

Other

Application for quotation of securities - BOT

25 May 2026

17KB

article

corporate_action

Notification of cessation of securities - BOT

21 May 2026

18KB

article

Other

Application for quotation of securities - BOT

13 May 2026

17KB

article

Other

Securities Trading Policy

8 May 2026

270KB

article

Other

Botanix announces change of address

6 May 2026

131KB

Event	Type	Confidence	Impact	Date	Status
BX002 Phase 2 acne topline data Phase 2 results for acne vulgaris candidate	data readout	Expected	arrow_upwardHigh	30 June 2026	Upcoming

expand_more22 past catalysts

SOFDRA quarterly revenue update Quarterly update filed (auto-resolved)	commercial milestone	Confirmed	arrow_upwardHigh	28 Apr 2026	Completed
Results posted — A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosisopen_in_new Results available at https://clinicaltrials.gov/study/NCT02336503	data readout	Confirmed	arrow_upwardHigh	13 Apr 2026	Completed
Results posted — A Non-Interventional Study To Assess Sweatingopen_in_new Results available at https://clinicaltrials.gov/study/NCT02552199	data readout	Confirmed	arrow_upwardHigh	13 Apr 2026	Completed
Results posted — A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 Gel in Subjectopen_in_new Results available at https://clinicaltrials.gov/study/NCT02682238	data readout	Confirmed	arrow_upwardHigh	13 Apr 2026	Completed
Results posted — Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Modeopen_in_new Results available at https://clinicaltrials.gov/study/NCT03824405	data readout	Confirmed	arrow_upwardHigh	13 Apr 2026	Completed
Results posted — Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperopen_in_new Results available at https://clinicaltrials.gov/study/NCT03948646	data readout	Confirmed	arrow_upwardHigh	13 Apr 2026	Completed
Results posted — A Confirmatory Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hopen_in_new Results available at https://clinicaltrials.gov/study/NCT03024255	data readout	Confirmed	arrow_upwardHigh	13 Apr 2026	Completed
Results posted — A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosisopen_in_new Results available at https://clinicaltrials.gov/study/NCT03627468	data readout	Confirmed	arrow_upwardHigh	13 Apr 2026	Completed
Results posted — A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosisopen_in_new Results available at https://clinicaltrials.gov/study/NCT03785587	data readout	Confirmed	arrow_upwardHigh	13 Apr 2026	Completed
Results posted — Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperopen_in_new Results available at https://clinicaltrials.gov/study/NCT03836287	data readout	Confirmed	arrow_upwardHigh	13 Apr 2026	Completed
Results posted — Evaluation of BTX 1503 in Patients With Moderate to Severe Acne Vulgarisopen_in_new Results available at https://clinicaltrials.gov/study/NCT03573518	data readout	Confirmed	arrow_upwardHigh	13 Apr 2026	Completed
Results posted — Evaluation of BTX 1503 in Patients With Moderate to Severe Acne Vulgarisopen_in_new Results available at https://clinicaltrials.gov/study/NCT03573518	data readout	Confirmed	arrow_upwardHigh	8 Apr 2026	Completed
Results posted — A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 Gel in Subjectopen_in_new Results available at https://clinicaltrials.gov/study/NCT02682238	data readout	Confirmed	arrow_upwardHigh	8 Apr 2026	Completed
Results posted — Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperopen_in_new Results available at https://clinicaltrials.gov/study/NCT03836287	data readout	Confirmed	arrow_upwardHigh	8 Apr 2026	Completed
Results posted — A Non-Interventional Study To Assess Sweatingopen_in_new Results available at https://clinicaltrials.gov/study/NCT02552199	data readout	Confirmed	arrow_upwardHigh	8 Apr 2026	Completed
Results posted — Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperopen_in_new Results available at https://clinicaltrials.gov/study/NCT03948646	data readout	Confirmed	arrow_upwardHigh	8 Apr 2026	Completed
Results posted — A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosisopen_in_new Results available at https://clinicaltrials.gov/study/NCT03785587	data readout	Confirmed	arrow_upwardHigh	8 Apr 2026	Completed
Results posted — A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosisopen_in_new Results available at https://clinicaltrials.gov/study/NCT02336503	data readout	Confirmed	arrow_upwardHigh	8 Apr 2026	Completed
Results posted — A Confirmatory Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hopen_in_new Results available at https://clinicaltrials.gov/study/NCT03024255	data readout	Confirmed	arrow_upwardHigh	8 Apr 2026	Completed
Results posted — Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Modeopen_in_new Results available at https://clinicaltrials.gov/study/NCT03824405	data readout	Confirmed	arrow_upwardHigh	8 Apr 2026	Completed
Results posted — A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosisopen_in_new Results available at https://clinicaltrials.gov/study/NCT03627468	data readout	Confirmed	arrow_upwardHigh	8 Apr 2026	Completed
AAD 2026 presentation Presented at AAD 2026 annual meeting (Mar 26-29, San Francisco)	conference presentation	Confirmed	removeMed	28 Mar 2026	Completed

Botanix Pharmaceuticals

Latest Insightprice-sensitive announcements & broker notes

3M Price

Pipeline Assets (2)

Capital Raises & Buybacks

Insider activity, holders, grants, publications

Director Transactions

Catalysts (23)· 1 upcoming · 22 past

Delivery Consistency Index

Announcements(20)

Quarterly Cash Flow

Substantial Holders (5%+ threshold)

Director Options & Rights

Short Interest

R&D Tax Incentive

Clinical Publications